Angiotensin‐converting enzyme inhibition prevents myocardial infarction‐induced increase in renal cortical cGMP and cAMP phosphodiesterase activities

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Fundamental & Clinical Pharmacology

• Publication date

  2015-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/fcp.12124PMID 25939307
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Different cross-talk sites between the renin–angiotensin and the kallikrein–kinin systems

  2014cited by this paper
• Temporal and spatial regulation of cAMP signaling in disease: role of cyclic nucleotide phosphodiesterases

  2014cited by this paper
• Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)

  2013cited by this paper
• Effectiveness and Safety of Phosphodiesterase 5 Inhibitors in Patients with Cardiovascular Disease and Hypertension

  2013cited by this paper
• The Pleiotropic Effects of Phosphodiesterase 5 Inhibitors on Function and Safety in Patients With Cardiovascular Disease and Hypertension

  2012cited by this paper
• Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

  2012cited by this paper
• Vasodilatory activity and antihypertensive profile mediated by inhibition of phosphodiesterase type 1 induced by a novel sulfonamide compound

  2012cited by this paper
• Cardiac Role of Cyclic-GMP Hydrolyzing Phosphodiesterase Type 5: From Experimental Models to Clinical Trials

  2012cited by this paper
• Mechanisms involved in increased plasma brain natriuretic peptide after heart transplantation.

  2011cited by this paper
• Concerted Regulation of cGMP and cAMP Phosphodiesterases in Early Cardiac Hypertrophy Induced by Angiotensin II

  2010cited by this paper
• PDEs1‐5 activity and expression in tissues of cirrhotic rats reveal a role for aortic PDE3 in NO desensitization

  2009cited by this paper
• Cyclic Nucleotide Phosphodiesterase (PDE) Inhibitors: Novel Therapeutic Agents for Progressive Renal Disease

  2007cited by this paper
• Renal hyporesponsiveness to brain natriuretic peptide: both generation and renal activity of cGMP are decreased in patients with pulmonary hypertension.

  2006cited by this paper
• Effect of short-term endurance training on exercise capacity, haemodynamics and atrial natriuretic peptide secretion in heart transplant recipients

  2006cited by this paper
• Novel therapeutic directions for the natriuretic peptides in cardiovascular diseases: what's on the horizon.

  2006cited by this paper
• Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.

  2006cited by this paper
• ACE inhibition prevents myocardial infarction-induced skeletal muscle mitochondrial dysfunction.

  2006cited by this paper
• Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications.

  2006cited by this paper
• Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure.

  2005cited by this paper
• Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction

  2005cited by this paper
• Role of Natriuretic Peptide Receptor Guanylyl Cyclase-A in Myocardial Infarction Evaluated Using Genetically Engineered Mice

  2005cited by this paper
• Quantitative Two-dimensional Echocardiographic Measurements Are Major Predictors of Adverse Cardiovascular Events After Acute Myocardial Infarction The Protective Effects of Captopril

  2005cited by this paper
• Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts.

  2005cited by this paper
• Cyclic AMP‐phosphodiesterases inhibitor improves sodium excretion in rats with cirrhosis and ascites

  2005cited by this paper
• Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4

  2004cited by this paper
• Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited.

  2004cited by this paper
• Mechanisms of renal hyporesponsiveness to ANP in heart failure

  2003cited by this paper
• Multiple Interactions Between the Renin-Angiotensin and the Kallikrein-Kinin Systems: Role of ACE Inhibition and AT1 Receptor Blockade

  2002cited by this paper
• Hormonal, renal, hemodynamic responses to acute neutral endopeptidase inhibition in heart transplant patients.

  2002cited by this paper
• Upregulation of Phosphodiesterase 1A1 Expression Is Associated With the Development of Nitrate Tolerance

  2001cited by this paper
• The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.

  2000cited by this paper
• Renal function, neurohormonal activation, and survival in patients with chronic heart failure.

  2000cited by this paper
• Cyclic Nucleotide Hydrolysis in Bovine Aortic Endothelial Cells in Culture: Differential Regulation in Cobblestone and Spindle Phenotypes

  2000cited by this paper
• Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney.

  1999cited by this paper
• Enhanced natriuretic response to neutral endopeptidase inhibition in heart-transplant recipients.

  1999cited by this paper
• Angiotensin II signaling activities the NO-cGMP pathway in rat proximal tubules.

  1998cited by this paper
• Is measurement of cyclic guanosine monophosphate in plasma or urine suitable for assessing in vivo nitric oxide production?

  1998cited by this paper
• Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention.

  1996cited by this paper
• Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure.

  1996cited by this paper
• Section Review: Cardiovascular & Renal: Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases

  1995cited by this paper
• Altered tissue degradation and distribution of atrial natriuretic peptide in patients with idiopathic dilated cardiomyopathy and its relationship with clinical severity of the disease and sodium handling.

  1995cited by this paper
• Formation of reactive oxygen metabolites in glomeruli is suppressed by inhibition of cAMP phosphodiesterase isozyme type IV.

  1994cited by this paper
• Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.

  1994cited by this paper
• Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation.

  1993cited by this paper
• Polycystic disease of the kidneys complicating the diagnosis of myocardial echinococcosis.

  1993cited by this paper
• Captopril enhances renal responsiveness to ANF in dogs with compensated high-output heart failure.

  1992cited by this paper
• Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation.

  1991cited by this paper
• Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure.

  1990cited by this paper
• Effect of converting-enzyme inhibition on renal response to ANF in rats with experimental heart failure.

  1990cited by this paper
• Kinin-related effects of angiotensin-converting enzyme inhibition.

  1990cited by this paper
• Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation.

  1990cited by this paper
• Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells.

  1990cited by this paper
• Angiotensin decreases cyclic GMP accumulation produced by atrial natriuretic factor.

  1987cited by this paper
• Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Lack of interconvertibility of major forms.

  1980cited by this paper
• Cyclic nucleotide phosphodiesterases in glomeruli of rat renal cortex.

  1978cited by this paper
• Cyclic nucleotide phosphodiesterase activities of pig coronary arteries.

  1975cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Hemodynamic, Hormonal, and Renal Actions of Phosphodiesterase-9 Inhibition in Experimental Heart Failure.

  2019cites this paper